The Serum Institute of India has produced more than 40 million doses of the Covishield coronavirus vaccine and has completed the registration of participants in the third phase of its trial, the Medical Research Council, India’s supreme body for biomedical research, said.
The Covishield vaccine was developed by the University of Oxford and the Austrian company AstraZeneca, in addition to India, it is being tested in the UK, Brazil, South Africa, and the USA.
“The Serum Institute of India and the Council for Medical Research are currently conducting Phase II and III clinical trials of Covishield at 15 different centers across the country. They completed the recruitment of all 1600 participants on October 31, 2020. Covishield is by far the most advanced vaccine in testing. Based on Phase II and III trials, the Serum Institute of India, through the Medical Research Council, will seek early access to this product for India Serum Institute of India has already produced 40 million doses of the vaccine under the license of the Comptroller General of India “, – the message says.
It is noted that soon the Serum Institute of India and the Medical Research Council will apply for the third phase of trials of another coronavirus vaccine, Covovax, developed by the American company Novavax.
India is currently testing three coronavirus vaccines – Bharat Biotech and Zydus Cadila are testing their Covaxin and ZycovD vaccines, and the Serum Institute of India is testing the Covishield vaccine. Also, the General Controller of Medicines of India (DCGI) approved the second and third phases of clinical trials of the Russian Sputnik V vaccine in India.